News & Updates

The combination of sintilimab plus axitinib demonstrates encouraging antitumour activity in patients with fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) while having a manageable safety profile, according to a phase II study conducted in China.

The use of glucagon-like peptide 1 (GLP-1) drugs such as semaglutide, dulaglutide, and the dual agonist tirzepatide helps boost testosterone levels in men with obesity and type 2 diabetes (T2D), according to new research.

Treatment with tofacitinib demonstrates effectiveness in patients with Blau syndrome (BS) who are resistant to tumor necrosis factor inhibitors (TNFi) or corticosteroids, reports a recent study.

Bimagrumab, when combined with semaglutide, enhances weight loss while preserving lean mass better than either treatment alone in the phase IIb BELIEVE study presented at ADA 2025.

Syrup

Film-coated tablet 10 mg and 20 mg

Chewable tablet 5 mg/5 mg

Tablet 500 mg/25 mg/2 mg

Capsule 100 mg